**Supplementary Fig. 1.** Distribution of department prescribing (A) sodium-glucose cotransporter 2 inhibitor and (B) glucagon-like peptide 1 receptor agonist according to the cause of established cardiovascular disease events. IHD, ischemic heart disease; PAD, peripheral artery disease; HHF, hospitalization for heart failure.